Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025
Rhea-AI Summary
Akero Therapeutics (NASDAQ: AKRO) announced two oral presentations and one poster at the 76th AASLD The Liver Meeting® 2025 in Washington, DC, Nov 7-11, 2025. Presentations will report 96-week data for efruxifermin (EFX) from the Phase 2b SYMMETRY study in compensated cirrhosis (F4c) due to MASH and AI-powered histology results from the Phase 2b HARMONY study in pre-cirrhotic (F2-F3) MASH.
Oral sessions are scheduled Nov 9, 2025 at 12:00 PM ET and 2:45 PM ET; the poster session is Nov 10, 2025 from 11:30 AM-12:30 PM ET.
Positive
- None.
Negative
- None.
Insights
Phase 2b 96-week data on efruxifermin will be presented at AASLD; signals reported but key endpoints and magnitudes are not disclosed.
Akero Therapeutics will present 96-week results from two Phase 2b programs—SYMMETRY (compensated cirrhosis, F4c) and HARMONY (pre-cirrhotic F2–F3)—at the AASLD meeting
The business mechanism: positive late-Phase 2 histology and non-invasive signals can raise the program's clinical value by supporting progression planning and regulatory discussions. Dependencies and risks: the release gives no quantitative endpoint results, responder rates, statistical significance, safety profile details, or prespecified primary endpoint outcomes; those facts determine regulatory and commercial impact. Statements of association should not be equated with definitive efficacy without the underlying numerical data.
Watch for the full datasets at AASLD on
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two upcoming oral presentations and a poster presentation at the 76th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025 taking place November 7-11, 2025, in Washington, DC. The presentations will highlight findings from the 96-week Phase 2b SYMMETRY study evaluating the safety and efficacy of lead product candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4c) due to metabolic dysfunction-associated steatohepatitis (MASH), along with insights from an AI-powered digital analysis of histology data from the 96-week Phase 2b HARMONY study in patients with pre-cirrhotic (F2-F3) MASH.
Details for the presentations are as follows:
Oral Presentations
Title: Efruxifermin was associated with improvements in multiple non-invasive tests indicative of fibrosis regression in participants with compensated cirrhosis due to MASH (SYMMETRY)
Presenter: Vlad Ratziu, M.D., Ph.D., Professor of Hepatology, Sorbonne Université and the Hôpital Pitié-Salpêtrière Medical School
Session: Clinical Plenary #1
Date/Time: Sunday, November 9, 2025, 12:00 PM ET
Title: Efruxifermin improved markers of portal hypertension as evaluated by Baveno VII criteria in compensated cirrhosis due to MASH: results from a 96-week, placebo-controlled, phase 2b trial
Presenter: Mazen Noureddin, M.D., M.H.Sc., Professor of Medicine, Houston Methodist Hospital and Director, Houston Research Institute
Session: MASH Clinical Trials
Date/Time: Sunday, November 9, 2025, 2:45 PM ET
Poster Presentation
Title: AI-powered histology analysis of HARMONY reveals Efruxifermin-driven changes in the liver microarchitecture in F2/F3 MASH
Presenter: Jörn M. Schattenberg, M.D., Professor of Medicine, Director of the Department of Medicine, Saarland University Medical Center, University of Saarland
Session: MASLD/MASH Therapeutics: New Agents and Approved / Available Agents
Date/Time: Monday, November 10, 2025, from 11:30 AM-12:30 PM ET
About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Akero’s lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, SYNCHRONY Outcomes in patients with compensated cirrhosis (F4c) due to MASH, and SYNCHRONY Real-World in patients with MASH or MASLD (metabolic dysfunction-associated steatotic liver disease). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and X for more information.
Investor Contact:
Christina Tartaglia
Precision AQ
212.362.1200
IR@akerotx.com
Media Contact:
Peg Rusconi
Deerfield Group
617.910.6217
Peg.rusconi@deerfieldgroup.com
FAQ
What data will Akero (AKRO) present at AASLD 2025?
When are Akero's oral presentations on efruxifermin at AASLD 2025?
What is the topic of Akero's AASLD 2025 poster for AKRO?
Where and when is the AKRO poster session at The Liver Meeting 2025?
Who will present Akero's SYMMETRY and HARMONY findings at AASLD 2025?
